Daiichi Sankyo Chief Talks Effient
FDA, late Friday, approved Daiichi Sankyo and Eli Lilly ’s Effient (prasugrel), a blood thinner designed to lower the chance of blood clots in patients undergoing angioplasty. The drug received a black box warning from the get go, warning doctors of an increased risk of bleeding. However, the fact that the two companies now have a competitor against Bristol-Myers Squibb and Sanofi Aventis’s blockbuster Plavix (clopidogrel bisulfate) is a huge boon, even if it is geared towards only a small